Expression and mutation of H-ras in uterine cervical cancer

被引:22
作者
Lee, JH
Lee, SK
Yang, MH
Ahmed, MM
Mohiuddin, M
Lee, EY
机构
[1] KYUNG HEE UNIV,COLL MED,DEPT PATHOL,SEOUL,SOUTH KOREA
[2] KYUNG HEE UNIV,COLL MED,DEPT GYNECOL,SEOUL,SOUTH KOREA
[3] UNIV KENTUCKY,DEPT RADIAT MED,LEXINGTON,KY 40506
[4] UNIV KENTUCKY,DEPT PATHOL,LEXINGTON,KY 40506
关键词
D O I
10.1006/gyno.1996.0188
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In cervical cancer, abnormalities of ras genes have not been fully investigated, We studied the expression and mutation of H-ras oncogene in cervical cancer to investigate their relationship and usefulness as an independent prognostic indicator, Twenty-seven paraffin-embedded resection specimens of cervical cancer (21 squamous, 3 adeno, 2 adenosquamous, and 1 small cell) were examined by immunohistochemistry using a mAb H-ras p21 and by PCR and allele-specific oligonucleotide hybridization using H-ras codon 12 and 61 amplimers and oligonucleotide probes. A strong immunoreaction was noted in 10 cases (37%) and weak immunoreaction in an additional 6 cases (22%), H-ras codon 12 mutations were detected in 6 of 27 cases (22%) and all of the mutations were guanine to adenine transitions, There was no mutation in codon 61, Cases with codon 12 mutations included all 3 squamous, 2 adeno, and 1 adenosquamous carcinoma. Only 3 of 16 (19%) cases with positive staining and 3 of 11 (27%) cases with negative staining showed mutations, No correlation was found between ras gene alterations and patient survival time, Our findings indicate that expression and mutation of H-ras oncogene occur in cervical cancer but their determination adds no useful prognostic information. (C) 1996 Academic Press, Inc.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 29 条
[1]   RAS ONCOGENES - THEIR ROLE IN NEOPLASIA [J].
BARBACID, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (03) :225-235
[2]   ALTERED GENE-PRODUCTS ARE ASSOCIATED WITH ACTIVATION OF CELLULAR RASK GENES IN HUMAN-LUNG AND COLON CARCINOMAS [J].
DER, CJ ;
COOPER, GM .
CELL, 1983, 32 (01) :201-208
[3]  
DIPAOLO JA, 1989, ONCOGENE, V4, P395
[4]   IMMUNODETECTION OF THE P21-RAS PRODUCTS IN HUMAN NORMAL AND PRENEOPLASTIC TISSUES AND SOLID TUMORS - A REVIEW [J].
GULBIS, B ;
GALAND, P .
HUMAN PATHOLOGY, 1993, 24 (12) :1271-1285
[5]   EXPRESSION OF RAS ONCOGENE PRODUCT AND EGF RECEPTOR IN CERVICAL SQUAMOUS-CELL CARCINOMAS AND ITS RELATIONSHIP TO LYMPH-NODE INVOLVEMENT [J].
HAYASHI, Y ;
HACHISUGA, T ;
IWASAKA, T ;
FUKUDA, K ;
OKUMA, Y ;
YOKOYAMA, M ;
SUGIMORI, H .
GYNECOLOGIC ONCOLOGY, 1991, 40 (02) :147-151
[6]  
ITO K, 1992, LAB INVEST, V66, pA65
[7]   AVOIDING FALSE POSITIVES WITH PCR [J].
KWOK, S ;
HIGUCHI, R .
NATURE, 1989, 339 (6221) :237-238
[8]  
LORINCZ AT, 1987, J NATL CANCER I, V79, P671
[9]   ANALYSIS OF KARYOTYPE, SCE, AND POINT MUTATION OF RAS ONCOGENE IN INDIAN MDS PATIENTS [J].
MANSOOR, AM ;
BHARADWAJ, TPR ;
SETHURAMAN, S ;
CHANDY, M ;
PUSHPA, V ;
KAMADA, N ;
MURTHY, PBK .
CANCER GENETICS AND CYTOGENETICS, 1993, 65 (01) :12-20
[10]  
MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0